Montag & Caldwell LLC Sells 3,366 Shares of Stryker Co. (NYSE:SYK)

Montag & Caldwell LLC trimmed its position in shares of Stryker Co. (NYSE:SYK - Free Report) by 7.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,100 shares of the medical technology company's stock after selling 3,366 shares during the period. Stryker makes up approximately 3.0% of Montag & Caldwell LLC's holdings, making the stock its 11th biggest holding. Montag & Caldwell LLC's holdings in Stryker were worth $14,078,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. J. W. Coons Advisors LLC increased its position in shares of Stryker by 0.7% in the 4th quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company's stock valued at $1,315,000 after acquiring an additional 26 shares during the period. Mascoma Wealth Management LLC raised its stake in shares of Stryker by 22.7% in the fourth quarter. Mascoma Wealth Management LLC now owns 146 shares of the medical technology company's stock valued at $53,000 after acquiring an additional 27 shares in the last quarter. Opal Wealth Advisors LLC boosted its stake in Stryker by 1.6% in the fourth quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company's stock valued at $654,000 after acquiring an additional 28 shares in the last quarter. Lindbrook Capital LLC grew its position in Stryker by 2.0% during the 4th quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company's stock worth $507,000 after purchasing an additional 28 shares during the last quarter. Finally, Alhambra Investment Management LLC boosted its holdings in shares of Stryker by 1.5% in the fourth quarter. Alhambra Investment Management LLC now owns 1,997 shares of the medical technology company's stock valued at $719,000 after acquiring an additional 29 shares in the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of the business's stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the transaction, the director now owns 3,642,075 shares of the company's stock, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by company insiders.

Stryker Stock Performance

Shares of SYK stock traded down $0.21 during midday trading on Friday, hitting $346.46. 1,349,873 shares of the company were exchanged, compared to its average volume of 1,362,954. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The firm's 50 day moving average price is $371.83 and its two-hundred day moving average price is $373.11. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19. The firm has a market capitalization of $132.24 billion, a P/E ratio of 44.65, a PEG ratio of 2.93 and a beta of 0.93.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping analysts' consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter last year, the company posted $3.46 EPS. As a group, equities research analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.84 per share. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.97%. Stryker's dividend payout ratio (DPR) is currently 43.30%.

Analyst Ratings Changes

A number of research analysts have issued reports on SYK shares. Citigroup restated a "buy" rating and issued a $450.00 target price on shares of Stryker in a report on Wednesday, February 26th. Truist Financial lifted their price objective on shares of Stryker from $409.00 to $413.00 and gave the company a "hold" rating in a research report on Thursday, January 30th. Argus set a $450.00 price objective on shares of Stryker in a research note on Monday, February 3rd. Barclays lifted their target price on shares of Stryker from $418.00 to $443.00 and gave the stock an "overweight" rating in a research report on Monday, February 10th. Finally, Stifel Nicolaus increased their target price on shares of Stryker from $400.00 to $440.00 and gave the stock a "buy" rating in a research report on Wednesday, January 29th. Five investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $423.53.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.